Management of Non-alcoholic Fatty Liver Disease and Steatohepatitis

Journal of Clinical and Experimental Hepatology

Volumn 2, Issue 2, 2012, Pages 156-173

  Le, Thuy Anh ^a   Loomba, Rohit ^b  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Colesevelam; Exenatide; Ezetimibe; Metformin; Pentoxifylline; S adenosylmethionine; Statins; Thiazolidinediones; Ursodeoxycholic acid; Vitamin E

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA GLUCOSIDASE INHIBITOR; ALPHA TOCOPHEROL; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIFIBROTIC AGENT; ANTIINFLAMMATORY AGENT; ASCORBIC ACID; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; BETAINE; BILE ACID SEQUESTRANT; COLESEVELAM; COLESTILAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EXENDIN 4; EZETIMIBE; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOSARTAN; METFORMIN; OBETICHOLIC ACID; PENTOXIFYLLINE; PIOGLITAZONE; PLACEBO; PRAVASTATIN; ROSIGLITAZONE; SIMVASTATIN; URSODEOXYCHOLIC ACID;

ABDOMINAL PAIN; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BLOATING; BODY MASS; DIARRHEA; DIET RESTRICTION; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TARGETING; DRUG WITHDRAWAL; EXERCISE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INSULIN RESISTANCE; INTERVENTION STUDY; LIFESTYLE MODIFICATION; LIPOLYSIS; LIVER FIBROSIS; LOW CALORY DIET; METABOLIC SYNDROME X; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OBESITY; PRIORITY JOURNAL; RISK REDUCTION; SIDE EFFECT; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 84864099851     PISSN: 09736883     EISSN: 22133453     Source Type: Journal    
DOI: 10.1016/S0973-6883(12)60104-2     Document Type: Article

References (111)

1. Vernon G, Baranova A, Younossi ZM Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011, 34:274-285.
2. Flegal KM, Carroll MD, Ogden CL, Curtin LR Prevalence and trends in obesity among US adults, 1999-2008. JAMA 2010, 303:235-241.
3. Adams LA, Lymp JF, St Sauver J, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005, 129:113-121.
4. Ong JP, Younossi ZM Epidemiology and natural history of NAFLD and NASH. Clin Liver Dis 2007, 11:1-16. vii.
5. Charlton MR, Burns JM, Pedersen RA, Watt KD, Heimbach JK, Dierkhising RA Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology 2011, 141:1249-1253.
6. Day CP, James OF Steatohepatitis: a tale of two "hits" ?. Gastroenterology 1998, 114:842-845.
7. Neuschwander-Tetri BA Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology 2010, 52:774-788.
8. Mari M, Caballero F, Colell A, et al. Mitochondrial free cholesterol loading sensitizes to TNF- and Fas-mediated steatohepatitis. Cell Metab 2006, 4:185-198.
9. Mari M, Colell A, Morales A, et al. Mechanism of mitochondrial glutathione-dependent hepatocellular susceptibility to TNF despite NF-kappaB activation. Gastroenterology 2008, 134:1507-1520.
10. Cortez-Pinto H, Chatham J, Chacko VP, Arnold C, Rashid A, Diehl AM Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: a pilot study. JAMA 1999, 282:1659-1664.
11. Savransky V, Bevans S, Nanayakkara A, et al. Chronic intermittent hypoxia causes hepatitis in a mouse model of diet-induced fatty liver. Am J Physiol Gastrointest Liver Physiol 2007, 293:G871-G877.
12. Piguet AC, Stroka D, Zimmermann A, Dufour JF Hypoxia aggravates non-alcoholic steatohepatitis in mice lacking hepatocellular PTEN. Clin Sci (Lond) 2009, 118:401-410.
13. Yang S, Lin H, Diehl AM Fatty liver vulnerability to endotoxin-induced damage despite NF-kappaB induction and inhibited caspase 3 activation. Am J Physiol Gastrointest Liver Physiol 2001, 281:G382-G392.
14. Spruss A, Bergheim I Dietary fructose and intestinal barrier: potential risk factor in the pathogenesis of nonalcoholic fatty liver disease. J Nutr Biochem 2009, 20:657-662.
15. Musso G, Gambino R, De Michieli F, Durazzo M, Pagano G, Cassader M Adiponectin gene polymorphisms modulate acute adiponectin response to dietary fat: possible pathogenetic role in NASH. Hepatology 2008, 47:1167-1177.
16. Marra F, Bertolani C Adipokines in liver diseases. Hepatology 2009, 50:957-969.
17. Li Z, Soloski MJ, Diehl AM Dietary factors alter hepatic innate immune system in mice with nonalcoholic fatty liver disease. Hepatology 2005, 42:880-885.
18. Maher JJ, Leon P, Ryan JC Beyond insulin resistance: innate immunity in nonalcoholic steatohepatitis. Hepatology 2008, 48:670-678.
19. Marchesini G, Brizi M, Bianchi G, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001, 50:1844-1850.
20. Pillai AA, Rinella ME Non-alcoholic fatty liver disease: is bariatric surgery the answer?. Clin Liver Dis 2009, 13:689-710.
21. Chavez-Tapia NC, Tellez-Avila FI, Barrientos-Gutierrez T, Mendez-Sanchez N, Lizardi-Cervera J, Uribe M Bariatric surgery for nonalcoholic steatohepatitis in obese patients. Cochrane Database Syst Rev 2010, 1:CD007340.
22. Rabl C, Campos GM The impact of bariatric surgery on nonalcoholic steatohepatitis. Semin Liver Dis 2012, 32:80-91.
23. Hardie DG Minireview: the AMP-activated protein kinase cascade: the key sensor of cellular energy status. Endocrinology 2003, 144:5179-5183.
24. Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M, Andreelli F Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond) 2012, 122:253-270.
25. Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001, 108:1167-1174.
26. Lin HZ, Yang SQ, Chuckaree C, Kuhajda F, Ronnet G, Diehl AM Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med 2000, 6:998-1003.
27. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M, Melchionda N Metformin in non-alcoholic steatohepatitis. Lancet 2001, 358:893-894.
28. Nair S, Diehl AM, Wiseman M, Farr GH, Perrillo RP Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. Aliment Pharmacol Ther 2004, 20:23-28.
29. Uygun A, Kadayifci A, Isik AT, et al. Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2004, 19:537-544.
30. Bugianesi E, Gentilcore E, Manini R, et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol 2005, 100:1082-1090.
31. Loomba R, Lutchman G, Kleiner DE, et al. Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2009, 29:172-182.
32. Shields WW, Thompson KE, Grice GA, Harrison SA, Coyle WJ The effect of metformin and standard therapy versus standard therapy alone in nondiabetic patients with insulin resistance and nonalcoholic steatohepatitis (NASH): a pilot trial. Therap Adv Gastroenterol 2009, 2:157-163.
33. Garinis GA, Fruci B, Mazza A, et al. Metformin versus dietary treatment in nonalcoholic hepatic steatosis: a randomized study. Int J Obes (Lond) 2010, 34:1255-1264.
34. Haukeland J, Konopski Z, Eggesbø H, et al. Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial. Scand J Gastroenterol 2009, 44:853-860.
35. Browning JD, Horton JD Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 2004, 114:147-152.
36. Semple RK, Chatterjee VK, O'Rahilly S PPAR gamma and human metabolic disease. J Clin Invest 2006, 116:581-589.
37. Pfutzner A, Hohberg C, Lubben G, et al. Pioneer study: PPARgamma activation results in overall improvement of clinical and metabolic markers associated with insulin resistance independent of long-term glucose control. Horm Metab Res 2005, 37:510-515.
38. Kon K, Ikejima K, Hirose M, et al. Pioglitazone prevents early-phase hepatic fibrogenesis caused by carbon tetrachloride. Biochem Biophys Res Commun 2002, 291:55-61.
39. Promrat K, Lutchman G, Uwaifo GI, et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 2004, 39:188-196.
40. Belfort R, Harrison SA, Brown K, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006, 355:2297-2307.
41. Aithal GP, Thomas JA, Kaye PV, et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 2008, 135:1176-1184.
42. Mofrad P, Contos MJ, Haque M, et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 2003, 37:1286-1292.
43. Adams LA, Sanderson S, Lindor KD, Angulo P The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 2005, 42:132-138.
44. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 2003, 38:1008-1017.
45. Ratziu V, Giral P, Jacqueminet S, et al. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled fatty liver improvement with rosiglitazone therapy (FLIRT) trial. Gastroenterology 2008, 135:100-110.
46. Ratziu V, Charlotte F, Bernhardt C, et al. Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial. Hepatology 2010, 51:445-453.
47. Idilman R, Mizrak D, Corapcioglu D, et al. Clinical trial: insulin-sensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2008, 28:200-208.
48. Omer Z, Cetinkalp S, Akyildiz M, et al. Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2010, 22:18-23.
49. Boettcher E, Csako G, Pucino F, Wesley R, Loomba R Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2012, 35:66-75.
50. Katoh S, Hata S, Matsushima M, et al. Troglitazone prevents the rise in visceral adiposity and improves fatty liver associated with sulfonylurea therapy-a randomized controlled trial. Metabolism 2001, 50:414-417.
51. Nissen SE, Wolski K Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007, 356:2457-2471.
52. Kolterman OG, Buse JB, Fineman MS, et al. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2003, 88:3082-3089.
53. Ratner RE, Maggs D, Nielsen LL, et al. Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus. Diabetes Obes Metab 2006, 8:419-428.
54. Ding X, Saxena NK, Lin S, Gupta NA, Anania FA Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology 2006, 43:173-181.
55. Svegliati-Baroni G, Saccomanno S, Rychlicki C, et al. Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis. Liver Int 2011, 31:1285-1297.
56. Gupta NA, Mells J, Dunham RM, et al. Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology 2010, 51:1584-1592.
57. Kenny PR, Brady DE, Torres DM, Ragozzino L, Chalasani N, Harrison SA Exenatide in the treatment of diabetic patients with non-alcoholic steatohepatitis: a case series. Am J Gastroenterol 2010, 105:2707-2709.
58. Hill DB, Devalaraja R, Joshi-Barve S, Barve S, McClain CJ Antioxidants attenuate nuclear factor-kappa B activation and tumor necrosis factor-alpha production in alcoholic hepatitis patient monocytes and rat Kupffer cells, in vitro. Clin Biochem 1999, 32:563-570.
59. Lee KS, Buck M, Houglum K, Chojkier M Activation of hepatic stellate cells by TGF alpha and collagen type I is mediated by oxidative stress through c-myb expression. J Clin Invest 1995, 96:2461-2468.
60. Phung N, Farrel G, Robertson G Vitamin E but not glutathione precursors inhibits hepatic fibrosis in experimental NASH exhibiting oxidative stress and mitochondrial abnormalities. Hepatology 2001, 34:361A.
61. Nobili V, Manco M, Devito R, Ciampalini P, Piemonte F, Marcellini M Effect of vitamin E on aminotransferase levels and insulin resistance in children with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2006, 24:1553-1561.
62. Nobili V, Manco M, Devito R, et al. Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial. Hepatology 2008, 48:119-128.
63. Lavine JE, Schwimmer JB, Van Natta ML, et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA 2011, 305:1659-1668.
64. Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010, 362:1675-1685.
65. Miller ER, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 2005, 142:37-46.
66. Klein EA, Thompson IM, Tangen CM, et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2011, 306:1549-1556.
67. Rozental P, Biava C, Spencer H, Zimmerman HJ Liver morphology and function tests in obesity and during total starvation. Am J Dig Dis 1967, 12:198-208.
68. Barak AJ, Beckenhauer HC, Junnila M, Tuma DJ Dietary betaine promotes generation of hepatic S-adenosylmethionine and protects the liver from ethanol-induced fatty infiltration. Alcohol Clin Exp Res 1993, 17:552-555.
69. Abdelmalek MF, Angulo P, Jorgensen RA, Sylvestre PB, Lindor KD Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. Am J Gastroenterol 2001, 96:2711-2717.
70. Abdelmalek MF, Sanderson SO, Angulo P, et al. Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial. Hepatology 2009, 50:1818-1826.
71. Duman DG, Ozdemir F, Birben E, et al. Effects of pentoxifylline on TNF-alpha production by peripheral blood mononuclear cells in patients with nonalcoholic steatohepatitis. Dig Dis Sci 2007, 52:2520-2524.
72. Wigg AJ, Roberts-Thomson IC, Dymock RB, McCarthy PJ, Grose RH, Cummins AG The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut 2001, 48:206-211.
73. Koppe SW, Sahai A, Malladi P, Whitington PF, Green RM Pentoxifylline attenuates steatohepatitis induced by the methionine choline deficient diet. J Hepatol 2004, 41:592-598.
74. Georgescu EF, Georgescu M Therapeutic options in non-alcoholic steatohepatitis (NASH). Are all agents alike? Results of a preliminary study. J Gastrointestin Liver Dis 2007, 16:39-46.
75. Satapathy SK, Sakhuja P, Malhotra V, Sharma BC, Sarin SK Beneficial effects of pentoxifylline on hepatic steatosis, fibrosis and necroinflammation in patients with non-alcoholic steatohepatitis. J Gastroenterol Hepatol 2007, 22:634-638.
76. Adams LA, Zein CO, Angulo P, Lindor KD A pilot trial of pentoxifylline in nonalcoholic steatohepatitis. Am J Gastroenterol 2004, 99:2365-2368.
77. Buranawati W, Thoun-U-Thaisri P, Pramoolsinsup C, Wisedopas N, Atamasirikul K, Udomsubpayakul U Pentoxifylline for treatment of nonalcoholic fatty liver disease (NAFLD): a randomized, placebo-controlled study. Thai J Gastroenterol 2007, 8:57-63.
78. Lee YM, Sutedja DS, Wai CT, et al. A randomized controlled pilot study of pentoxifylline in patients with non-alcoholic steatohepatitis (NASH). Hepatol Int 2008, 2:196-201.
79. Van Wagner LB, Koppe SW, Brunt EM, et al. Pentoxifylline for the treatment of non-alcoholic steatohepatitis: a randomized controlled trial. Ann Hepatol 2011, 10:277-286.
80. Zein CO, Yerian LM, Gogate P, et al. Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial. Hepatology 2011, 54:1610-1619.
81. Bellentani S Immunomodulating and anti-apoptotic action of ursodeoxycholic acid: where are we and where should we go?. Eur J Gastroenterol Hepatol 2005, 17:137-140.
82. Neuman M, Angulo P, Malkiewicz I, et al. Tumor necrosis factor-alpha and transforming growth factor-beta reflect severity of liver damage in primary biliary cirrhosis. J Gastroenterol Hepatol 2002, 17:196-202.
83. Laurin J, Lindor KD, Crippin JS, et al. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology 1996, 23:1464-1467.
84. Lindor KD, Kowdley KV, Heathcote EJ, et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 2004, 39:770-778.
85. Adams LA, Angulo P, Petz J, Keach J, Lindor KD A pilot trial of high-dose ursodeoxycholic acid in nonalcoholic steatohepatitis. Hepatol Int 2010, 4:628-633.
86. Leuschner UF, Lindenthal B, Herrmann G, et al. High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial. Hepatology 2010, 52:472-479.
87. Ratziu V, de Ledinghen V, Oberti F, et al. A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis. J Hepatol 2011, 54:1011-1019.
88. Loomba R, Wesley R, Pucino F, Liang TJ, Kleiner DE, Lavine JE Placebo in nonalcoholic steatohepatitis: insight into natural history and implications for future clinical trials. Clin Gastroenterol Hepatol 2008, 6:1243-1248.
89. Roglans N, Sanguino E, Peris C, et al. Atorvastatin treatment induced peroxisome proliferator-activated receptor alpha expression and decreased plasma nonesterified fatty acids and liver triglyceride in fructose-fed rats. J Pharmacol Exp Ther 2002, 302:232-239.
90. Egawa T, Toda K, Nemoto Y, et al. Pitavastatin ameliorates severe hepatic steatosis in aromatase-deficient (Ar-/-) mice. Lipids 2003, 38:519-523.
91. Rallidis LS, Drakoulis CK, Parasi AS Pravastatin in patients with nonalcoholic steatohepatitis: results of a pilot study. Atherosclerosis 2004, 174:193-196.
92. Gomez-Dominguez E, Gisbert JP, Moreno-Monteagudo JA, Garcia-Buey L, Moreno-Otero R A pilot study of atorvastatin treatment in dyslipemid, non-alcoholic fatty liver patients. Aliment Pharmacol Ther 2006, 23:1643-1647.
93. Hyogo H, Tazuma S, Arihiro K, et al. Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia. Metabolism 2008, 57:1711-1718.
94. Nelson A, Torres DM, Morgan AE, Fincke C, Harrison SA A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: a randomized placebo-controlled trial. J Clin Gastroenterol 2009, 43:990-994.
95. Garcia-Calvo M, Lisnock J, Bull HG, et al. The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc Natl Acad Sci USA 2005, 102:8132-8137.
96. Deushi M, Nomura M, Kawakami A, et al. Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome. FEBS Lett 2007, 581:5664-5670.
97. Yoneda M, Fujita K, Nozaki Y, et al. Efficacy of ezetimibe for the treatment of non-alcoholic steatohepatitis: an open-label, pilot study. Hepatol Res 2010, 40:613-621.
98. Promrat K, Kleiner DE, Niemeier HM, et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010, 51:121-129.
99. Zelber-Sagi S, Kessler A, Brazowsky E, et al. A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2006, 4:639-644.
100. Harrison SA, Fecht W, Brunt EM, Neuschwander-Tetri BA Orlistat for overweight subjects with nonalcoholic steatohepatitis: a randomized, prospective trial. Hepatology 2009, 49:80-86.
101. Rosenson RS, Abby SL, Jones MR Colesevelam HCl effects on atherogenic lipoprotein subclasses in subjects with type 2 diabetes. Atherosclerosis 2009, 204:342-344.
102. Goldberg RB, Fonseca VA, Truitt KE, Jones MR Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy. Arch Intern Med 2008, 168:1531-1540.
103. Sonnett TE, Levien TL, Neumiller JJ, Gates BJ, Setter SM Colesevelam hydrochloride for the treatment of type 2 diabetes mellitus. Clin Ther 2009, 31:245-259.
104. Taniai M, Hashimoto E, Tobari M, et al. Treatment of nonalcoholic steatohepatitis with colestimide. Hepatol Res 2009, 39:685-693.
105. Le TA, Chen J, Changchien C, et al. Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: a randomized controlled trial. Hepatology 2012.
106. Georgescu EF Angiotensin receptor blockers in the treatment of NASH/NAFLD: could they be a first-class option?. Adv Ther 2008, 25:1141-1174.
107. Hirose A, Ono M, Saibara T, et al. Angiotensin II type 1 receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis. Hepatology 2007, 45:1375-1381.
108. Yokohama S, Tokusashi Y, Nakamura K, et al. Inhibitory effect of angiotensin II receptor antagonist on hepatic stellate cell activation in non-alcoholic steatohepatitis. World J Gastroenterol 2006, 12:322-326.
109. Georgescu EF, Ionescu R, Niculescu M, Mogoanta L, Vancica L Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis. World J Gastroenterol 2009, 15:942-954.
110. Yokohama S, Yoneda M, Haneda M, et al. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 2004, 40:1222-1225.
111. Torres DM, Jones FJ, Shaw JC, Williams CD, Ward JA, Harrison SA Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: a 12-month randomized, prospective, open-label trial. Hepatology 2011, 54:1631-1639.